18F-D4-FCH in MIBC
Research type
Research Study
Full title
Feasibility study of uptake of 18F-D4-Fluorocholine (18F-D4-FCH) PET/CT and correlation with choline kinase alpha expression in Muscle Invasive Bladder Cancer (MIBC).
IRAS ID
153297
Contact name
Stephen Mangar
Contact email
Sponsor organisation
Imperial College London and Imperial College Healthcare NHS Trust
Research summary
Feasibility study of uptake of 18F-D4-Fluorocholine (18F-D4-FCH) PET/CT and correlation with choline kinase alpha expression in Muscle Invasive Bladder Cancer (MIBC).
Bladder cancer is the seventh most common cancer in the UK and accounts for 3% of all cancer deaths. At diagnosis, 15-20% of patients will have muscle invasive bladder cancer. The diagnosis of bladder cancer is made at cystoscopy with a transurethral resection of bladder tumour (TURBT), and standard treatment for muscle invasive disease is radical cystectomy and pelvic lymph node dissection.Pelvic lymph node involvement is a major prognostic factor and can occur in up to 20% of patients at time of surgery. The accuracy of conventional standard imaging such as CT is limited especially for detection of nodal disease. CT provides accuracy for lymph node staging in the range of 70-90% with false-negative rates of 35-40%. Therefore, there is a clear need for improved pre-operative nodal staging to allow for better patient selection for surgery and selection of those that would benefit from chemotherapy up-front before surgery but also to exclude those with spread of the disease. We have a type of scan called a PET (positron Emission Tomography)scan that uses a small amount of radioactive substance called a "tracer 18F-D4-FCH". We hope to show that this tracer is taken up by the cancer cells in the bladder , enabling us to get more information about the tumour and if it has spread elsewhere.REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
14/EM/1109
Date of REC Opinion
22 Aug 2014
REC opinion
Favourable Opinion